Defining the potency of amikacin against Escherichia coli Klebsiella pneumoniae Pseudomonas aeruginosa and Acinetobacter baumannii derived from Chinese hospitals using CLSI and inhalation-based breakpoints

摘要

ObjectivesWe report the in vitro activity of amikacin and comparators against Gram-negative bacteria collected from blood and respiratory specimens in China during a 1-year period between December 2015 and December 2016.